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Glioblastoma (GBM) is one of the most devastating and deadly types of tumor. Among all the present
treatment strategies, the utmost prerequisite is prolonged intervention at the malignant site. The
blood–brain barrier (BBB) is the bottleneck in the delivery of anti-GBM drugs and invasive treatment
comes with many pitfalls. This review will discuss the potential of embedding antitumor drugs into
nanocarriers for intranasal delivery. Additionally, it emphasizes the significance of applying quality
by design (QbD) methodology from the early development stages to ensure the high quality, safety
and efficacy of the developed carrier system.Introduction
Malignant gliomas (MGs) are the most lethal forms of primary
central nervous system (CNS) malignancy, classified based on an
augmenting level of undifferentiation, anaplasia and prolifera-
tion. WHO classified gliomas into four clinical grades: grade I
(astrocytoma); grade II (diffuse astrocytoma, the most distin-
guished form); grade III (anaplastic variants of astrocytoma);
and grade IV (glioblastoma) [1]. Pleomorphic glioblastoma is
called glioblastoma multiforme (GBM) because these malignant
cells show a discrepancy in structure and morphology [2]. The
current treatment strategies for GBM include surgery, radiothera-
py and chemotherapy. The focus of researchers to treat GBM is
challenging because surgery and radiotherapy are not good
options because of its topographically diffuse nature [3]. Eventu-
ally, understanding the pattern of spread of individual malignant
cells over long distances and into parts of the brain is essential for
patient survival. A present literature survey reveals that there are
just a few available therapies that could significantly improve
survival chances [4]. The circumvention of the blood–brain barrier
(BBB) through straight intervention into insubstantial brain tis-
sues can result in severe neurotoxicity and loss of brain key
functionality. Consequently, there is a need to design a more
specific and rational (noninvasive) approach to target GBM. It is
also necessary to explore the potential differences in permeabilityPlease cite this article in press as: Sabir, F. et al.
Corresponding author: Csoka, I. (csoka@pharm.u-szeged.hu)
1359-6446/ã 2019 Published by Elsevier Ltd.
https://doi.org/10.1016/j.drudis.2019.10.005 between the intact and malignant brain to overcome the chal-
lenges in brain targeting [5]. Figure 1 demonstrates the differences
between barriers in the intact brain and in glioblastoma.
The intranasal route is a direct and simple approach, including
many advantages of higher bioavailability, shorter onset of ac-
tion, circumvention of systemic toxicity, noninvasiveness and
clearance. Additionally, avoiding the BBB could significantly
increase the concentration of the active pharmaceutical agent
in the central nervous system (CNS). According to data present in
the literature, pharmacological active agents can be delivered
through the nasal cavity via the trigeminal and olfactory nerves.
Drug permeation is basically dependent upon the key character-
istics of an active agent or carrier, like its metabolic stability,
solubility, residence time in the mucous layer and rate of muco-
ciliary clearance [6].
The safety and toxicological evaluation of products delivered
intranasally is of great importance. The prolonged contact of
formulations containing cytotoxic materials can cause ciliotoxi-
city, tissue damage and irritation [7]. Therefore, regardless of the
presence of carrier-free approaches for intranasal delivery, a
carrier system could be useful to deliver chemotherapeutics via
the intranasal route; among all delivery systems, nanoparticle-
based carriers have been intensely studied for research imaging,
treatment and diagnosis of brain tumors. Lipid-based colloidal
systems, for example liposomes and solid lipid nanoparticles,
increased drug transfer to the brain through the intranasalwww.drugdiscoverytoday.com 1
ro
fo
a
[l
p
s
t
t
o
d
a
e
sQ16
REVIEWS Drug Discovery Today Volume 00, Number 00 October 2019
DRUDIS 2566 1–10
Immune cell
release factors
Blood
Epithelial barrier fenestrated vessels
CSF
Continous endothelial
Astrocyte endfoot
Pericyte
Basement
membrane
Lipophilic
diffusion
Fenestra
Leaky junction
Invading and growing
tumor cells
Enhanced
permeability
leakage
Altered active
efflux transport
Detached
astrocyte
Act
ive
 eff
lux
tra
nsp
ort
(a)
(b)
(c)
Blood CSF barrier
Drug Discovery Today 
FIGURE 1
Challenges in blooQ1 d to brain delivery in a brain tumor. The figure illustrates the comparison between barriers in normal brain and in glioblastoma multiforme
(GBM). (a) Normal blood–brain barrier (BBB) composed of: astrocyte (role in morphology), pericyte, endothelial cells (role in tight junction structure and
vasoregulation). (b) Blood–tumor barrier (deatched astrocyte, fenestra, leaky juctions – blood vessels that supply the tumor are leaky and incompletely formed
but the healthy brain components are still present in the main region of GBM). (c) Blood–cerebrospinal-fluid (CSF) barrier (composed of a choroid plexus having
epithelial cells and tight junctions, increased level of albumin in the CSF in GBM which might cause disturbance of the BBB or release from tumor).
2
Review
s
P
O
ST
SC
R
EENoute [8]. For instance, in vitro hemolysis and cytotoxicity studies
f doxorubicin (DOX)-loaded liposomal nanoparticles were per-
rmed, which resulted in specificity and enhanced levels of drug
ccumulation in gliomas [9,10]. Colloidal nanocarrier systems
iposomes, solid lipid nanoparticles (SLNs), lipoproteins, lipo-
lexes, etc.] have shown clear amassing in gliomas but the
hortening of noninvasive accumulation and retention evalua-
ion tools could hinder monitoring the exact duration and loca-
ion of nanoparticles within the brain [11]. This review will focus
n the potential of lipid nanocarrier systems to deliver anticancer
rugs via the intranasal route, as well as the significance of
pplying quality by design (QbD) software for the targeted deliv-
ry of cytotoxic materials via the intranasal route to maintain the
afety and product profile.Please cite this article in press as: Sabir, F. et al.
 www.drugdiscoverytoday.comStrategies to circumvent the BBB: bottleneck in
targeting glioblastoma
Scientists have been working to develop versatile methods to
circumvent the BBB, which include the opening of the BBB,
intranasal delivery and penetration via the BBB by cellular inter-
nalization. The overexpression of receptors (like low-density lipo-
protein, nicotinic acetylene choline, insulin-like growth factor
(IGF), transferrin receptors, diphtheria toxin, leptin and scavenger
receptor type B) has been reported on the BBB. The specific ligand
functionalization and attachment can intervene in drug transport
via the BBB. This precise and sensitive type of interaction between
ligands and receptors governs receptor-mediated transport
[12–14]. However, there are limitations in implementation of a
functionalized or specific ligand attached moiety. First, it can lose
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Nits therapeutic activity; second, all present strategies are invasive
and accumulation of drug cargos in the liver and other off-target
sites governs its therapeutic efficacy [7]. Therefore, there is a need
for noninvasive delivery approaches to achieve the best therapeu-
tic goals.
An alternative route of administration
An alternative route of administration to CNS drug delivery is
intranasal administration. The intranasal delivery (IND) route is a
noninvasive, direct and more effective route of administration
than intravenous (i.v.) delivery and can avoid the BBB together
with systemic side effects. The IND pathways (trigeminal and
olfactory pathways) in the nasal cavity are reasons for direct
delivery to the brain and result in good pharmacokinetic/pharma-
codynamic (PK/PD) profiles for CNS drugs. Drug delivery from the
nose via the trigeminal pathway follows either axonal or endocy-
totic transport, whereas the olfactory pathway is further divided
into intraneuronal and extraneuronal pathways. The intraneur-
onal pathway follows axonal transport and it takes hours or days
for the API to reach the target site, whereas the extraneuronal path
follows the perineural route and it just takes a few minutes to reach
the target site [15,16]. Furthermore, this delivery route is a new
approach for the delivery of potent active agents and for antineo-
plastic agents that can be loaded into nanocarriers to ensure a
better safety profile. By using this route, nanoparticles can carry
drugs easily to the target site, and can bypass the main barriers: the
BBB and the blood–cerebrospinal-fluid barrier (BCSFB). There are
many studies revealing better target delivery of CNS drugs via the
intranasal route in contrast to i.v. administration. Schioth et al.
reported that IGF-1, when given intranasally, had greater CNS
efficacy when compared with i.v. intervention. Many other studies
also showed that the intranasal delivery of the API led to better
cure rates of CNS diseases, such as depression, autism, eating
disorders, Parkinson’s disease (PD) and Huntington’s disease
(HD), as well as various other diseases yet to be treated. Besides
these advantages, there is a long list of factors that can limit the
permeability of drug carriers via the intranasal route. Therefore,
while designing intranasal formulations, the factors regarding the
anatomy and the physiology of the nasal cavity should be consid-
ered. The vibrissae of the nasal vestibule and the transepithelial
region of the atrium (narrowest region) are the parts that are the
least permeable. By contrast, other parts like the superior, middle
and inferior turbinate of the respiratory region are more perme-
able, whereas the specialized ciliated olfactory nerve cells of the
olfactory region have direct access to the CSF. Table 1 explains
how the structures of the nasal cavity affect permeability via
the intranasal route [16,17]. By considering the crucial factorsPlease cite this article in press as: Sabir, F. et al.
TABLE 1
Impact of various structural characteristics of nasal cavity on perm
Structural parts/region of the nasal cavity Effe
Nasal hairs (vibrissae) of the nasal vestibule (sebaceous glands) Leas
Transepithelial region of the atrium (narrowest region) Less
pres
Superior, middle and inferior turbinate of the respiratory region Mos
supp
Specialized ciliated olfactory nerve cells of the olfactory region Dire
Ciliated cells and squamous epithelial cells of the nasopharynx Nasaaffecting drug delivery via the nasal cavity, a formulation can
be designed for nose-to-brain delivery with increased permeation,
low clearance and high mucoadhesion by the application of
the QbD [18].
Nanocarrier systems for nose-to-brain delivery
The safety data for intranasal formulations are of great importance.
Nanoparticles have the potential to improve nose-to-brain deliv-
ery because they have can avoid enzymatic degradation and
transport from P-glycoprotein (P-gp) efflux proteins. These carrier
systems can enhance therapeutic brain delivery by using bioad-
hesive materials and also by opening the closed junctions of the
nasal epithelial membrane. The transport of nanoparticles
through the intranasal route takes place via olfactory neurons
by endocytotic or neuronal pathways. The confocal microscopy
study of polystyrene nanoparticles reported that nanocarriers
within the range 20–200 nm can follow clathrin-coated pits;
however, nanoparticles in the size range 200–1000 nm can be
transported via caveolae-mediated endocytosis [7,15].
Nanoparticles can also follow the transport from endothelial
cells to olfactory neurons via endocytosis or pinocytosis and
move along the axon. For this transport pathway, the size of
nanoparticles should be within the diameter of the axon, which is
up to 100–700 nm. Therefore, the intranasal delivery of nano-
particles could be a promising choice for targeting life-threaten-
ing diseases like glioblas Qtoma. Regarding the carrier systems, the
essential classes of nanoparticles that are at the center of focus for
brain targeting include polymeric nanoparticles such as micelles,
iron oxide nanoparticles, gold nanoparticles, quantum dots and
lipid-based nanoparticles like nano lipid carriers (NLCs), SLNs,
liposomes, lipoplexes and lipopro Qteins [19]. In general, nanopar-
ticles can induce toxicity depending upon their internalization
site and composition. It is also reported that nanoparticles can
induce inflammation, DNA damage and oxidative stress. The IND
of metal nanoparticles into brain is relatively well known for
harmful neurological effects. The extensive exposure of metal
nanoparticles can cause serious damage and even can lead to
diseases such as Alzheimer’s disease (AD) and parkinsonism. The
present study is relevant to lipid nanoparticles that are most
biocompatible and least toxic in nature. Clearance of nanopar-
ticles from the brain occurs via the mononuclear phagocytes
system (MPS). The aspects of toxicity and clearance via
macrophages are not accurate and might be caused by
variations in nanoparticles properties (like charge, shape, size,
coating) and use of different quantification methods [20]. Figure 2
explains the nanoparticle attributes influencing drug delivery
via the intranasal route.eation
ct on permeation Refs
t permeable owing to the presence of keratinized cells [17]
 permeable because it has a small surface area and stratified cells are
ent anteriorly
[35]
t permeable region due to greater surface area and increased blood
ly
[36]
ct pathway to cerebrospinal fluid (CSF) [35]
l cavity drainage receiver [17]
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FIGURE 2
Nanoparticle attribQ2 utes influencing the delivery of API via the intranasal route. The figure illustrates the significant features of nanoparticles for intranasal
delivery like pysiochemical properties (size, charge, composition) and other significant features such as low immunogenicity, low toxicity, avoiding mucociliary
clearance andQ3 increased retention time (high mucoadhesivity).
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elivery
or significant nose-to-brain delivery, a colloidal drug delivery
ystem is the most suitable system that refers to increased bio-
vailability and sustained release and high stability of the API. The
nhanced biocompatibility, high scalability, safety and efficacy of
pid nanoparticles made them superior carriers for nose-to-brain
elivery. In contrast to lipid nanoparticles, polymeric nanoparti-
les have low scalability, high cytotoxicity (e.g., 100% mortality
as reported when cells were treated with polyester polymer
anoparticles) and poor tolerability. Most lipid nanoparticles have
 particle size within the range 50–1000 nm. As described in the
revious section, a particle size between 50 and 700 nm is the most
vorable for intranasal delivery via neuronal transport [15].
mong these lipid carriers, liposomes and SLNs discussed in the
llowing section have shown greater therapeutic efficacy in
BM. The lipid nanoformulations of anticancer agents provide
nhanced drug stability, PK, drug distribution and efficacy com-
ared with other approaches [7].
herapeutic efficacy of lipid nanoparticles in targeting
lioblastoma
iposomes, SLNs, lipoproteins, lipoplexes and nanostructured
pid carriers have been widely used for targeting glioblastoma.Please cite this article in press as: Sabir, F. et al.
 www.drugdiscoverytoday.comLiposomes are bilayer spherical biocompatible carriers and these
lipid-based nanostructures are actually the pioneers of lipid-based
particles employed for parenteral delivery with diameter ranges
from 10 to 1000 nm and are precursors of NLCs an Q2d SLNs [21].
Table 2 summarizes the use of liposomes in the management of
MGs via different delivery routes. The results of all these studies
revealed an increase in survival time along with the inhibition of
proliferation [22]. It should be considered that various liposomal
factors like the size, particle diameter and uptake by the MPS can
be crucial for targeting [23].
Lipid nanoparticles including SLNs and NLCs are the most
suitable among all other lipid nanoparticles, without being con-
strained by their limitations. The stealth ability of lipid nanopar-
ticles is higher than other polymeric nanoparticles against the MPS
because they are fabricated from biocompatible substances such as
a brew of natural lipids [24]. Table 3 demonstrates the therapeutic
efficacy of SLNs and NLCs in targeting glioblastoma. The results of
all previous studies revealed the decrease in tumor growth, the
increase in the lifespan of the animals used and the inhibition of
cell proliferation.
The proven efficacy (from studies mentioned in Tables 2 and 3)
of lipid nanoparticles in targeting glioblastoma has shown their
potential to encapsulate anticancer drugs. Furthermore, these lipid
nanoparticles have a good ability to protect the loaded API and,
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TABLE 2
Applications of liposomes in the management of glioblastoma multiforme (GBM)
Encapsulated substance Model of study Type of liposomes Central nervous system (CNS) action/effects
on GBM
Refs
Doxorubicin Clinical study PEG-liposomes Enhanced efficacy
Inhibition of tumor growth
Enhanced survival time
[37]
Interferon (IFN)-b
Plasmid
Clinical study Cationic liposomes Antiproliferative
Reduction of tumor size
[38]
Recombinent herpes
simplex
virus thymidines kinase
(adeno viral carrier)
Glioma model in
mouse
Cationic liposomes Reduced immunogenicity
Antiproliferative
[39]
Antisense growth factor Human
malignant glioma
cell lines
Cationic liposomes Inhibition of tumor growth [40]
Lomustine Rabit glioma
model
Temperature-sensitive
liposomes (TSL)
Thermo targeting with inhibition of tumor growth [41]
EPI pluQ7 s celecoxib Mice PTD peptide attached liposomes Destruction of glioma vasculogenic mimicry channels [42]
PTQ8 X Mice Dual targeting, cell penetrating
peptid attached liposomes
Selective targeting
Inhibition of tumor growth
[43]
siRNA Mice Ligand-targeted liposomes (CTX) Enhance the efficacy and internalization into glioma
cells
[40]
DNR and quinacrine Mice Ligand-targeted liposomes
(WGA and TAM)
Killing of glioblastoma cells and dimishing brain
gliomas
[44]
DOX and iron oxidQ9 e Mice Ligand-targeted liposomes (RGD) Enhance targeting ability and site-specific delivery [45]
Irinotecan Rats Ligand-targeted liposomes Inhibit tumor growth increase lifespan of rats [46]
DOX Rats Lactoferrin liposomes Destruction of tumor cells and significant enhanced
survival rate in tumor-bearing rats
[47]
TABLE 3
Summary of applications of SLNs/NLCs in targeting glioblastoma multiforme (GBM)
Encapsulated substance Model of study Type of SLN/NLCs Central nervous system (CNS) action/
effects on GBM
Refs
Carmustine U87 cell line (In vitro human brain model) Cationic solid lipid nanoparticles
(CASLNs)
Antiproliferative effect
Decrease expression of tumor necrosis
factor (TNF)-a
[48]
Doxorubicin and etoposide U87 cell lines, HBMEC, human astrocytes CASLNs Significant reduction in tumor growth [49]
Edelfosine (EDF) Glioma cell line C6 in vivo C6 glioma
xenograft tumor
SLNs (composed of compritolor) The antimalignant effect, inhibition of
tumor growth
[50]
Cytarabine (CRB) EL-4 cell lines NLCs Cytotoxic effect on tumor cell line [51]
siRNAs U87MG cell lines and tumor xenograft for in
vivo study
Low-density lipoprtoein (LDL)
and polyethylene glycol (PEG)
SLNs
The decrease in tumor cell proliferation [52]
Camptothecin (CPT) BCEC Porcine brain capillary endothelial
cells compared with (RAW264.7)
CA-SLNs Higher cytotoxicity in brain cells
enhance antitumor efficacy
[53]
Etoposide K562 cell line, MTT assay and flow
cytometry
NLCS with transferrin Enhanced cellular uptake and
antiproliferative effect
[54]
Locked nucleic acid (LNA)
(antioncogenic miR-21)
U87 MG (malignant glioma cell line) Lipid nanocapsule (LNCs) with
L-1 peptide
Reduction of miR-21 expression and
antiproliferative
[55]
Curcumin U251MG cell line, rats bearing C6 gliomas CA-LNCs The decrease in tumor size and
malignancy
[56]
Resveratrol (RVR) U87 cell line Functionalized SLNs Enhance cytotoxicity [57]
Doxorubicin (DOX) BBB model (hcmec/D3 cell) CA-SLNs Increased toxicity for glioblastoma cells [58]
Polo-like kinase 1(PLK1)
siRNAs (siPLK1)
Rats bearing orthotopic xenograft model HA-LNPs (hyaluronic acid) Increased cell death (by reducing
expression of PLK1)
[59]
Temozolomide (TMZ) U87MG in vitro cells lines NLCs Very much enhanced antitumor activity [60]
Vincristine (VCR) and TMZ U87MG in vitro cell line and mice induced
with malignant glioma model
SLNs and NLCs NLCS show better antitumor activity
than SLNs
[61]
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Nbecause of their occlusive nature, they can also increase nasal
retention time. These features make lipid nanoparticles a signifi-
cant carrier for nose-to-brain delivery because they can avoid the
cytotoxicity issues of antineoplastic drugs [7,25].Please cite this article in press as: Sabir, F. et al.Novel lipid nanoparticle formulation for targeting
glioblastoma via IND
New delivery approaches are required in research to efficiently
target brain tumors. Curcumin-loaded NLCs (CUR-NLC) forwww.drugdiscoverytoday.com 5
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EENtranasal administration were developed with a particle diame-
er of 146 nm, encapsulation efficiency (EE) of 90%, a charge of
1 mV and polydispersity index (PDI) rating of 0.18. The results
f the following investigation reveal the increased cytotoxicity of
UR-NLC compared with that of free CUR in the glioma cell line
373MG. The biodistribution study for the same formulation
howed an increased drug concentration in the brain after the
tranasal application of NLCs. The results of this study led to
he conclusion that CUR-NLC is an efficient delivery system
r targeting glioblastoma [23]. Temozolomide-loaded NLCs
MZ-NLC) were prepared to ensure brain targeting via the
tranasal route. The optimized formulation showed a particle
ize within the nano range, zeta potential of 15 mV, entrapment
fficiency of 81% and PDI of 0.2. The results of the in vivo studies
dicated the significant enhanced brain concentration of
MZ-NLC in comparison with TMZ dispersion (i.v., intranasal).
he highest concentration of TMZ-NLC in the brain proved the
fficacy of this direct intranasal administration of NLCs. The
llowing study described that the intranasal administration of
LCs increased residence time and resulted in higher bioavail-
bility in the brain at lower doses, denoting this delivery route
he most suitable for targeting glioma [26].
Novel farnesyl thio salicylic acid (FTA)-loaded lipid cationic
ybrid nanoparticles (HNPs) were formulated and evaluated for
ntitumor activity via the intranasal route. Glioma 2 (RG2) cells
ere placed into Wistar rats. The tumor-bearing rats were treated
ith FTA-encapsulated HNPs by intranasal and i.v. administra-
ion. The evaluation of tumor sizes with FTA-encapsulated HNPs
esulted in a clear decrease (55%) in tumor size. This study
roved that the intranasal intervention of FTA-loaded HNPs is
n equally effective approach in glioblastoma targeting. The
esults of all studies support the use of the IND route for targeting
lioblastoma by using lipid carriers [27].
echanism of nanoparticle drug delivery via the
tranasal route
he intranasally administered formulation will deposit on the
seudostratified columnar epithelium (a respiratory tract in the
asal cavity). The site of deposition of the intranasal formula-
ion administered in the form of solution, spray or gel (via
pplicator) is the front region of the nasal cavity. However,
here are a few devices that can settle the drug formulation in a
igher region of the nasal cavity. The nanoparticles intervene
ia intranasal passage deposited at the site of the nasal cavity
epending on its properties like size, charge and lipophilicity.
here are four options for the drug, either to enter via the nasal
pithelial tissue and arrive at the circulation or be unloaded
long the gastrointestinal tract (GIT) through the nasopharynx
y the ciliary clearance network. The system is made up of cilia,
hich are motile and beat in a synchronized manner, thereby
ropelling the viscous superior part dorsally against the naso-
harynx quickly (5 mm/min). In addition, enzymatic activity is
lso higher in the nasal cavity deep in the olfactory region
enzymes like cytochrome P450 dependent peptidases, mono-
xygenase and proteases are involved in that procedure) [28].
he nose-to-brain delivery of the nanoparticles will follow the
ransport from endothelial cells to the olfactory neurons viaPlease cite this article in press as: Sabir, F. et al.
 www.drugdiscoverytoday.comendocytosis or pinocytosis and move along the axon or it will
follow the trigeminal nerve pathway. For this transport path-
way, the size of nanoparticles should be within the diameter of
the axon: 100–700 nm [29]. Figure 3 explains all the possible
mechanisms and pathways involved in the transport of lipid
nanoparticles.
In vitro/in vivo/ex vivo models for testing nose-to-brain
delivery
For an exploration of the mechanism behind the transport of
drugs via the intranasal route, different types of in vitro, in vivo
and ex vivo models are used. These diverse types of models are
applied for different studies: in vitro models for permeation and
diffusion studies; in vivo models for the determination of
absorption and PK profile of the API; and ex vivo models for
perfusion studies in the nasal cavity. The selection of in vivo
models should be adequate for studying the anatomy of the
nasal cavity. The first animal model used for intranasal study
was the rat and, later, with the development in absorption
data, other animal models like sheep, monkey, mouse and
rabbit were also used. For adequate PK studies rabbit, dog,
sheep and monkey models are commonly suggested, whereas
mouse and rat models are used for preliminary absorption
studies [30].
Besides the significance of in vivo models, the transport
mechanism of drug absorption from the nasal route had to
be explored. In vitro models were fabricated to replace the in
vivo and ex vivo models. Furthermore, it is difficult to extrapo-
late the data of the absorption and kinetics studies obtained
from the animal models to humans (owing to the difference of
species). It is necessary to select adequate cell lines that can
reproduce results at significantly low costs. There are a number
of in vitro cell culture models like NAS2BL (originating from rat
nasal squamous carcinoma), BT (originating from bovine tur-
binates), CaCo-2 cell lines (from human colon carcinoma),
Calu-3 (originating from human lung adenocarcinoma), RPMI
2650 (from human nasal epithelial tissues) and 16HBE14o-
(from human normal bronchial epithelium of male heart lung
transplant patient) [30]. Among these models, CaCo-2 and
RPMI 2650 are used to evaluate permeability and absorption
via the nasal route. However, there are some disadvantages of
cell lines, for example RPMI 2650 are undifferentiated cells
that encounter the limited expression of ciliated and goblet
cells. The absence of a developed monolayer makes this cell
line impractical to use for a transport study. By contrast, Calu-
3 cells can develop monolayers and are suitable for transport
study but the origin of this cell line is not the normal epithelial
cells of the nasal cavity. The 16HBE14o- cell line possesses high
transepithelial electrical resistance (TEER) making it suitable
for transportation study but this cell line originates from
normal bronchial epithelium of a male heart and lung trans-
plant patient. For the determination of drug delivery and the
development of formulations via the intranasal route, it is
important to use reliable ex vivo models. The excised tissue
is usually from the nasal mucosa of slaughtered or experimen-
tal animals (rats, rabbits, dogs, monkeys, sheep) or from
humans as well. The ex vivo study is very important to obtain
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FIGURE 3
Possible mechaQ4 nisms of lipid nanoparticles across the nasal membrane. The figure demonstrates that lipid nanoparticles with enhanced mucoadhesivity will
follow four possible pathways: (i) airway; (ii) nasal vein; (iii) neurological pathway; and (iv) mucociliary clearance. The nanoparticles will follow the transport from
endothelial cells to olfactory neurons via endocytosis or pinocytosis and move along the axon or follow the trigeminal nerve pathway.
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Nall the information regarding the toxicity, efflux, metabolism
and permeation of the developed formulation. Besides the
many advantages of ex vivo models, there are a few limitations,
such as the lack of interstitial flow rate determination and the
thickness of nasal epithelial tissues of the excised mucosa. The
Ussing chamber is the ex vivo nasal model for permeability
studies [31].
Significance of QbD in the early development of a lipid
carrier system for targeting glioblastoma
Depending on up-to-date knowledge about barriers limiting the
IND of anticancer drugs targeting brain tumors, lipid-based nano-
carrier systems could offer a promising strategy. However, becausePlease cite this article in press as: Sabir, F. et al.many formulation parameters and regulatory aspects should be
considered, the QbD concept or the GMP of the 21st century
should be followed. The main elements of QbD methodology
are described in the relevant guidelines of the International Coun-
cil on Harmonization (ICH), specifically ICH Q8 (R2), Q9 and Q10;
and these include: (i) defining the quality target product profile
(QTPP); (ii) selecting the critical quality attributes (CQAs) of the
targeted product; (iii) selecting the production method and defin-
ing the critical process parameters (CPPs) that can highly affect the
CQAs; and (iv) analysis of the initial risk assessment (RA), which is
followed by optimizing the level of the risky factors by applying a
suitable design of experiment (DOE) [32]. The very first step of
QbD is to collect all the data from previous studies that could affectwww.drugdiscoverytoday.com 7
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FIGURE 4
Steps and elemenQ5 ts of quality by design (QbD) methodology that will help to design and validate the process for development of intranasal formulation. Step
1: identification of target product profile (TPP) and quality target product profile (QTPP), which comprises therapeutic and other quality requirements. Step 2:
identification of critical quality attributes (CQAs), which are associated with in-process materials, and critical process parameters (CPPs) having an effect on
CQAs. Step 3: risk assessment (RA) is a process of collecting information to support risk decision and it is also a main activity of QbD methodology that can be
performed at initial and final phases of development.
8
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s
P
O
ST
SC
R
EENhe target product profile. After early knowledge of space design
nd evaluation of QTPPS, CQAs and CPPs, the RA application
evealed the attributes having the highest impact on the final lipid
anoformulation quality for IND. Figure 4 demonstrated the
escription of QbD methodology in early development of a lipid
arrier system for nose-to-brain delivery based on the relevant ICH
uidelines [33,34].
oncluding remarks and future directions
his review summarizes the importance of nose-to-brain de-
very in targeting GBM. Nanoformulations are considered as
ne of the most important targeting carriers. Besides many
dvantages, nanoformulations loaded with cytotoxic material
an still accumulate in other parts and tissues of the body, for
stance in the liver, spleen and kidney. Therefore, it is neces-
ary to design and fabricate a method that can overcome thePlease cite this article in press as: Sabir, F. et al.
 www.drugdiscoverytoday.comshortcomings of previously used carriers and delivery routes.
The alternative route and the lipid nanocarrier provide
chances to deliver anticancer drugs (with potential efficacy)
against GBM, and this will be a new and expedient approach to
GBM treatment strategies. Furthermore, for successful IND of
anticancer drugs, risk assessment is the main component of
QbD which should be applied using special software to calcu-
late the risk severity of CQAs and CPPs regarding the encapsu-
lation of potential API into lipid-based carrier systems. Thus,
the application of the QbD concept can save time and effort by
directing the focus toward structuring the quality in each step
of formulation design.
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